Trial | NCT01301222  Report issue

Title

Role of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft Pancreas
Randomized Controlled Trial on Role of Octreotide in Preventing Pancreatic Fistula and Complications After Pancreaticoduodenectomy in Patients With Soft Pancreas

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    octreotide ...

  • Study Participants

    110
This randomized controlled trial (RCT) aims at assessing the influence of octreotide on pancreatic fistula or complications following pancreatoduodenectomy in patients with soft pancreas. Previously reported trials have included all types of pancreatic resections and have include all types of pancreas and have shown no clearcut benefit of octreotide after pancreaticoduodenectomy (PD). Soft pancreas and normal sized duct are the risk factors for fistula following PD. This study's focus is on this select group of patients and aims to assess the role of octreotide in patients with soft pancreas.
Study design: Prospective open labeled randomized trial. AIM: Study aims at assessing the influence of octreotide on pancreatic fistula or complications following pancreatoduodenectomy in patients with soft pancreas.
Study Started
Sep 30
2010
Primary Completion
Sep 30
2014
Study Completion
Feb 28
2015
Last Update
Feb 24
2015
Estimate

Drug Inj. Octreotide

100 mcg subcutaneously for 5 days

  • Other names: Inj Octride

octreotide Experimental

octreotide arm 100mcg for 5 days. control has no octreotide

Criteria 

Inclusion Criteria:elective surgery patients undergoing pancreatoduodenectomy

soft pancreas, no dilated duct

Exclusion Criteria:

age > 75 years old
documented chronic pancreatitis
previous pancreatic surgery
previous gastric surgery vagotomy
documented pancreatic duct dilatation
No Results Posted